10393 San Diego Mission Rd, Suite 120
San Diego, CA 92108-2134
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
This spontaneous drawing demonstrates neglect of left-sided details. (Contributed by Dr. Anjan Chatterjee.)
Sep. 28, 2020
Epilepsy & Seizures
Myoclonic seizures are sudden, brief, involuntary, single or multiple jerks that are isolated or rapidly repetitive and are due to abnormal excessive or synchronous neuronal activity in the brain. They can be positive or negative, spontaneous or evoked, generalized or focal, and cortical or thalamocortical, and represent clinical manifestations of numerous epileptic syndromes of different etiology.
Aug. 18, 2021
Neuropharmacology & Neurotherapeutics
Sep. 16, 2020
Childhood Degenerative & Metabolic Disorders
The congenital disorders of glycosylation syndromes constitute a group of severe syndromes with a broad phenotypic expression within and between subtypes. In most patients there are signs of nervous system involvement where typical manifestations include structural abnormalities, developmental delay, intellectual disability, stroke-like episodes, epileptic seizures, myopathies, myasthenia, and demyelinating neuropathy. A majority (60%) can be detected using a transferrin glycosylation test.
Jun. 01, 2013
Oct. 21, 2020
Jan. 10, 2020
Manifestations of drug-induced myopathy range from muscle pain and stiffness, to muscle weakness and myokymia, to rhabdomyolysis in severe cases. Muscle tissue is sensitive to drugs due to its high metabolic activity and potential sites for disruption of energy-producing pathways, with elevated serum creatine kinase being the most sensitive indicator of muscle damage.
Oct. 08, 2020
Neurofibromatosis 1 (NF1) is a common autosomal dominant neurocutaneous disorder displaying a typical pattern of dermatologic and systemic findings. NF1 is characterized by 2 of the following 7 criteria: 6 café-au-lait spots, skinfold freckles, 2 neurofibromas or 1 plexiform neurofibroma, 2 Lisch nodules, distinctive osseous lesion, optic pathway glioma, and/or a first-degree relative with neurofibromatosis 1.
Jan. 03, 2021